European committee takes a second look at Alzheimer's drug and now says it should be approved

The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended the approval of Alzheimer's treatment lecanemab, known as Leqembi in the U.S., after a previous rejection due to concerns about side effects.